Sensei Biotherapeutics (SNSE) to Release Earnings on Friday

Sensei Biotherapeutics (NASDAQ:SNSE) is expected to be releasing its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect Sensei Biotherapeutics to post earnings of ($4.81) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 10:30 AM ET.

Sensei Biotherapeutics Price Performance

Shares of SNSE opened at $29.49 on Thursday. The company’s 50-day moving average is $20.56 and its 200-day moving average is $13.46. The firm has a market capitalization of $37.16 million, a PE ratio of -1.54 and a beta of -0.12. Sensei Biotherapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $36.76.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNSE has been the topic of a number of research reports. Wall Street Zen upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.